Owen Mumford Pharmaceutical Services, a division of Owen Mumford Ltd., has introduced its new Aidaptus auto-injector platform after completing development. Aidaptus is a 2-step, spring-powered, single-use auto-injector with a flexible design that fits both 1mL and 2.25mL prefilled glass syringes in one base device. The platform includes stopper sensing technology and a self-adjusting plunger that adapts to different stopper positions and varying fill volumes in each syringe, with no need to switch out parts. The auto-injector comes with two spring strengths to support a range of drug viscosities.
Aidaptus offers an innovative, patient-focused design featuring automatic needle insertion for a user-friendly and consistent experience. The stopper sensing technology, along with independent, two-phase needle insertion and medication delivery, greatly reduces force on the syringe, lowering the risk of breakage during use. With a needle guarded before, during, and after injection, Aidaptus gives peace of mind to new auto-injector users and those uncomfortable with needles. Users can also feel confident the injection is complete with audible cues at the start and finish. Plus, a bright yellow plunger rod is visible through a large window to confirm the injection is done.
Aidaptus is offered in two platform styles: a clear outer body with color overwrap for quick window size selection, or a classic opaque housing, providing flexibility for both branding and customization, as well as options for market segmentation and product lifecycle management. Its compact form demonstrates high standards in sustainable design and human factors engineering, achieved throughout development and with attention to efficient final assembly by applying design for manufacture (DfM) principles.
“Our Aidaptus auto-injector platform was created to support the growing use of subcutaneous injections for treating chronic illnesses such as rheumatoid arthritis, Crohn’s disease, and multiple sclerosis,” said Michael Earl, Director, Owen Mumford Pharmaceutical Services. “As more care moves outside hospitals, Aidaptus will help patients self-administer therapy easily with a straightforward device. At the same time, it can help reduce complexity and risk for pharmaceutical and biotech companies’ combination products by adapting to various syringe sizes and fill volumes. During drug development or lifecycle management, these parameters might change—now, the device can stay the same.”
Aidaptus was designed to handle changes in drug formulation or injection volume, so it can help manage risks during drug development and throughout the product lifecycle.
To learn more about the new OMPS Aidaptus auto-injector platform, visit: https://api.owenmumford.com/aidaptus